Research Article
BRAF Mutations in an Italian Regional Population: Implications for the Therapy of Thyroid Cancer
Table 2
Correlation of BRAF status and clinicopathological characteristics.
| | | BRAF status | | | BRAF wild-type | BRAF-mutated |
| | Cytology diagnosis: | | | | Thy 3 | 34/38 (90%) | 6/38 (16%) | | Thy 4 | 10/18 (56%) | 8/18 (44%) | | Final histology: | | | | FTC | 5/42 (12%) | 0/14 (0%) | | PTC | 2/42 (5%) | 11/14 (79%) | | Nodular hyperplasia colloid or follicular adenoma | 28/42 (67%) | 2/14 (14%) | | mPTC | 3/42 (7%) | 0/14 (0%) | | Combined cell carcinoma and PTC | 1/42 (2.25%) | 0/14 (0%) | | MTC | 1/42 (2.25%) | 0/14 (0%) | | Hurtle neoplasia | 1/42 (2.25%) | 0/14 (0%) | | fPTC | 1/42 (2.25%) | 1/14 (7%) |
|
|
PTC = papillary thyroid carcinoma; FTC = follicular thyroid carcinoma; MTC = medullary thyroid carcinoma; fPTC = follicular variant of papillary carcinoma; mPTC = papillary microcarcinoma.
|
